The Goldman Sachs Group, Inc. 13D and 13G filings for Akero Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-07 4:31 pm Sale | 2022-12-30 | 13G | Akero Therapeutics, Inc. AKRO | GOLDMAN SACHS GROUP INC GS | 474,564 1.000% | -1,301,628 (-73.28%) | Filing |
| 2022-02-08 4:19 pm Purchase | 2021-12-31 | 13G | Akero Therapeutics, Inc. AKRO | GOLDMAN SACHS GROUP INC GS | 1,776,192 5.100% | 1,776,192 (New Position) | Filing |